Statin-associated myopathy with normal creatine kinase levels

Annals of Internal Medicine

Volumn 137, Issue 7, 2002, Pages 581-585

  Phillips, Paul S ^a   Haas, Richard H ^a   Bannykh, Sergei ^a   Hathaway, Stephanie ^a   Gray, Nancy L ^a   Kimura, Bruce J ^a   Vladutiu, Georgirene D ^a   England, John D F ^a  

^a SCRIPPS MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CYTOCHROME C OXIDASE; MEVINOLIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; STATIN;

ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; LIPID STORAGE; MALE; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 0036787034     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-7-200210010-00009     Document Type: Article

References (19)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57. [PMID: 9841303]
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-9. [PMID: 7968073]
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9. [PMID: 8801446]
4. Farmer JA. Learning from the cerivastatin experience. Lancet. 2001;358: 1383-5. [PMID: 11705478]
5. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin [Letter]. Aust N Z J Med. 1995;25: 374-5. [PMID: 8540887]
6. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [Letter]. Atherosclerosis. 1999;143:459-60. [PMID: 10217378]
7. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf, 2000;22:441-57. [PMID: 10877038]
8. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995;131:163-74. [PMID: 7878672]
9. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol. 1998;152:99-106, [PMID: 9772205]
10. Marino M, Nicholas JA, Gleim GW, Rosenthal P, Nicholas SJ. The efficacy of manual assessment of muscle strength using a new device. Am J Sports Med. 1982;10:360-4. [PMID: 7180955]
11. Dubowitz V. Muscle Biopsy - A Practical Approach. London: Ballliere Tindall; 1985.
12. Stubbs RJ, Schwartz MS, Gerson RJ, Thornton TJ, Bayne WF. Comparison of plasma profiles of lovastatin (mevinolin), simvastatin (epistatin) and pravasratin (epstatin) in the dog. Drug Invest. 1990; 2(Suppl 2):18-28.
13. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999;84: 811-5. [PMID: 10513779]
14. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH, Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-9. [PMID: 11505177]
15. Lanctǒt KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther. 1995;58:692-8. [PMID: 8529335]
16. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000;34:630-8. [PMID: 10852092]
17. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Nad Acad Sci U S A. 1989; 86:2379-82. [PMID: 2928337]
18. Phillips P, Haas R, Barshop B, Bannykh S, Amjadi D. Utility of abnormal 3-methylglutaconic aciduria (3MGA) in diagnosing statin associated myopathy. Atheroscler Thromb Vasc Biol (Online Journal). 2002;22:878.
19. Scaglia F, Sutton VR, Bodamer OA, Vogel H, Shapira SK Naviaux RK, et al. Mitochondrial DNA depletion associated with partial complex II and IV deficiencies and 3-methyloutaconic aciduria. J Child Neurol. 2001;16:136-8. [PMID: 11292221]